Skip to main content
Ir a la página de inicio de la Comisión Europea (se abrirá en una nueva ventana)
español es
CORDIS - Resultados de investigaciones de la UE
CORDIS

Stable ²¹¹At-labeled radiopharmaceuticals for targeted α therapy

Descripción del proyecto

La unión estable de la astatina-211 contribuye a mejorar la radioterapia contra el cáncer

La terapia dirigida con emisores alfa está diseñada para administrar radiaciones altamente energéticas directamente a las células cancerosas mediante la unión de un emisor alfa a una molécula dirigida contra el cáncer. El emisor alfa astatina-211 (211At), que se comporta de forma similar a los metales y los halógenos, es muy prometedor debido a su vida media extremadamente corta. El desarrollo de radiofármacos marcados con 211At se centra actualmente en el enlace carbono-At, que ha demostrado ser inestable «in vivo», lo que provoca una liberación prematura y la irradiación de tejidos sanos. Mediante métodos analíticos y computacionales recientemente disponibles compatibles con concentraciones traza, el equipo del proyecto SAt-Radio, financiado por el CEI, investigará estrategias de enlace alternativas basadas tanto en las propiedades halógenas como metálicas del 211At para liberar el potencial de este emisor alfa en la lucha contra el cáncer.

Objetivo

Astatine (At) is the rarest naturally occurring element on Earth, exhibiting only short-lived radioisotopes. One of them, ²¹¹At, decays with a half-life of 7.2 h by emission of a highly energetic alpha particle, making it one of the rare alpha emitters suitable for targeted alpha therapy (TAT) of cancers, if bound to an appropriate cancer targeting molecule. Because the number of cyclotrons able to produce it has seen a significant rise in the past years, it is expected that ²¹¹At will become more accessible and play a major role in the development of TAT.

Astatine belongs to the halogen elements, and despite more than 80 years since its discovery, many chemical properties remain to be discovered. This lack of knowledge is due to the absence of stable isotopes and the availability in minute amounts that preclude the use of standard analytical methods. Yet, research has shown that At behaves similarly to metals but also to halogens, forming bonds similar to its closest homologue, iodine, such as the carbon-At bond. This strategy is the main approach currently available to develop ²¹¹At-labeled radiopharmaceuticals. Yet, a lack of in vivo stability of the C-At bond is often observed, resulting in the release of ²¹¹At before it reaches its target and leading to irradiation of healthy tissues. Improving this stability is therefore a major challenge that remains to be overcome in order to unleash the potential of ²¹¹At in cancer treatments.

In this context the objective of the SAt-Radio project is to explore alternative bonding modalities to the C-At bond in order to develop novel radiolabeling approaches with improved in vivo stability. The strategies developed will exploit both the halogen and the metallic character of At, using analytical and computational approaches that have recently become available and making possible to elucidate the chemistry of this enigmatic elements at the trace concentration it is available.

Ámbito científico (EuroSciVoc)

Palabras clave

Programa(s)

Tema(s)

Régimen de financiación

HORIZON-ERC - HORIZON ERC Grants

Ver todos los proyectos financiados en el marco de este régimen de financiación

Convocatoria de propuestas

(se abrirá en una nueva ventana) ERC-2022-COG

Ver todos los proyectos financiados en el marco de esta convocatoria

Institución de acogida

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS
Aportación neta de la UEn
€ 2 222 875,00
Coste total
€ 2 357 165,00

Beneficiarios (2)